About lumasiran
Hydroxy acid oxidase 1-targeting siRNA
Used for
- Treats primary hyperoxaluria type 1, a rare inherited disorder causing excess oxalate.
Usual adult dose
Weight-based subcutaneous loading doses monthly for three doses, then maintenance every three months.
Usual dose in children
Weight-based subcutaneous dosing; used from birth, with schedule based on age and weight.
Common side effects
- Injection-site reactions, such as redness, pain or swelling
- Abdominal pain
- Headache
Important warnings
- Dosing depends on body weight; follow the prescribed schedule.
- Injection-site reactions are usually mild and temporary.
Pregnancy
Human pregnancy data are limited; potential risks are not established.
Breastfeeding
It is unknown whether lumasiran passes into breast milk; effects on infants are uncertain.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.